Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.61 |
| ▸ | ESRRA | P11474 | 1/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.46 |
| ▸ | PPARA | Q07869 | 4/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3243745 | 0.99 | PPARG (0.60) | PPARGESRRAFFAR1PPARAKDR | |
| SCHEMBL3245024 | 0.94 | PPARG (0.66) | PPARGESRRAFFAR1PPARAKDR | |
| SCHEMBL3237905 | 0.90 | PPARG (0.65) | PPARGESRRAFFAR1PPARAKDR | |
| SCHEMBL3244103 | 0.90 | PPARG (0.62) | PPARGESRRAFFAR1PPARANTRK1 | |
| SCHEMBL6543779 | 0.89 | PPARG (0.75) | PPARGESRRAFFAR1PPARA | |
| SCHEMBL3246164 | 0.88 | PPARG (0.61) | PPARGESRRAFFAR1PPARA | |
| SCHEMBL3251633 | 0.88 | PPARG (0.68) | PPARGESRRAFFAR1PPARAKDR | |
| Hydrochloric Acid SCHEMBL6544899 | 0.88 | PPARG (0.74) | PPARGESRRAFFAR1PPARA | |
| SCHEMBL3243649 | 0.88 | PPARG (0.69) | PPARGESRRAFFAR1PPARA | |
| SCHEMBL3243267 | 0.87 | PPARG (0.62) | PPARGESRRAFFAR1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | PPARG 929/4885ESRRA 961/4885FFAR1 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.